Rhinology future trends

2017 EUFOREA debate on allergic rhinitis

G Scadding, J Bousquet, C Bachert, W J Fokkens, P W Hellings, E Prokopakis, O Pfaar, D Price

Research output: Contribution to journalArticle

Abstract

The 2nd Rhinology Future Debate, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases) was held in Brussels in December 2017. One of these debates addressed the position of MP-AzeFlu in allergic rhinitis (AR) treatment. The current article summarizes this debate; reviewing recent data, and exploring how this has been interpreted by experts and incorporated into AR management guidelines and a clinical decision support system (CDSS). The Allergic Rhinitis & its Impact on Asthma (ARIA) guideline position MP-AzeFlu firstline for the treatment of AR, and in preference to intranasal corticosteroids (INSs) during the first 2 weeks of treatment. The AR CDSS recommends MP-AzeFlu as one of the firstline treatments for patients with a visual analogue scale (VAS) score lower than 5/10 cm, and in preference (along with INS) for those with a VAS score equal or higher than5/10 cm. Panellists agreed that AR management should be kept as simple as possible, with some preferring a one treatment fits all approach, while others preferred a step-up approach. The need to change the AR management mentality was acknowledged, accepting that most patients use their medication as needed and use multiple treatments; AR medications are needed which have a very fast onset of action and which target breakthrough symptoms. Panellists agreed that MP-AzeFlu has a role to play here, since it has a 5 minute onset-of-action, provides clinically-relevant symptom relief in 15 mins and AR control in less than 3 days, targets nasal hyper-reactivity (NHR) which likely contributes to uncontrolled AR and breakthrough symptoms, and provides more effective AR symptom relief than INS monotherapy or INS + oral antihistamine. Finally, experts considered it likely that MP-AzeFlu should have a greater impact on asthma control than INS in co-morbid patients, but clinical data is required to back up existing pharmacoeconomic evidence. The next Rhinology Future Debate will be in held in Brussels in Dec 2019.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalAmerican Journal of Rhinology
Volume57
Issue number1
Early online date27 Jul 2018
DOIs
Publication statusPublished - 2019

Fingerprint

Adrenal Cortex Hormones
Clinical Decision Support Systems
Visual Analog Scale
Allergic Rhinitis
Therapeutics
Asthma
Guidelines
Pharmaceutical Economics
Histamine Antagonists
Nose
Hypersensitivity
Education
Research

Keywords

  • Journal Article
  • MP-AzeFlu
  • Nasal hyperresponsiveness
  • Allergic rhinitis
  • Patient preference
  • Asthma
  • Guidelines
  • LONG-TERM
  • INTRANASAL THERAPY
  • MOMETASONE FUROATE
  • NASAL HYPERREACTIVITY
  • asthma
  • ADVANCED DELIVERY-SYSTEM
  • patient preference
  • IMPACT
  • nasal hyperresponsiveness
  • FLUTICASONE PROPIONATE
  • AZELASTINE HYDROCHLORIDE
  • ASTHMA
  • guidelines
  • QUALITY-OF-LIFE
  • allergic rhinitis

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Scadding, G., Bousquet, J., Bachert, C., Fokkens, W. J., Hellings, P. W., Prokopakis, E., ... Price, D. (2019). Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. American Journal of Rhinology, 57(1), 49-56. https://doi.org/10.4193/Rhin18.076

Rhinology future trends : 2017 EUFOREA debate on allergic rhinitis. / Scadding, G; Bousquet, J; Bachert, C; Fokkens, W J; Hellings, P W; Prokopakis, E; Pfaar, O; Price, D.

In: American Journal of Rhinology, Vol. 57, No. 1, 2019, p. 49-56.

Research output: Contribution to journalArticle

Scadding, G, Bousquet, J, Bachert, C, Fokkens, WJ, Hellings, PW, Prokopakis, E, Pfaar, O & Price, D 2019, 'Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis', American Journal of Rhinology, vol. 57, no. 1, pp. 49-56. https://doi.org/10.4193/Rhin18.076
Scadding G, Bousquet J, Bachert C, Fokkens WJ, Hellings PW, Prokopakis E et al. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. American Journal of Rhinology. 2019;57(1):49-56. https://doi.org/10.4193/Rhin18.076
Scadding, G ; Bousquet, J ; Bachert, C ; Fokkens, W J ; Hellings, P W ; Prokopakis, E ; Pfaar, O ; Price, D. / Rhinology future trends : 2017 EUFOREA debate on allergic rhinitis. In: American Journal of Rhinology. 2019 ; Vol. 57, No. 1. pp. 49-56.
@article{0842502b95ba4079a0cc0029d723702c,
title = "Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis",
abstract = "The 2nd Rhinology Future Debate, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases) was held in Brussels in December 2017. One of these debates addressed the position of MP-AzeFlu in allergic rhinitis (AR) treatment. The current article summarizes this debate; reviewing recent data, and exploring how this has been interpreted by experts and incorporated into AR management guidelines and a clinical decision support system (CDSS). The Allergic Rhinitis & its Impact on Asthma (ARIA) guideline position MP-AzeFlu firstline for the treatment of AR, and in preference to intranasal corticosteroids (INSs) during the first 2 weeks of treatment. The AR CDSS recommends MP-AzeFlu as one of the firstline treatments for patients with a visual analogue scale (VAS) score lower than 5/10 cm, and in preference (along with INS) for those with a VAS score equal or higher than5/10 cm. Panellists agreed that AR management should be kept as simple as possible, with some preferring a one treatment fits all approach, while others preferred a step-up approach. The need to change the AR management mentality was acknowledged, accepting that most patients use their medication as needed and use multiple treatments; AR medications are needed which have a very fast onset of action and which target breakthrough symptoms. Panellists agreed that MP-AzeFlu has a role to play here, since it has a 5 minute onset-of-action, provides clinically-relevant symptom relief in 15 mins and AR control in less than 3 days, targets nasal hyper-reactivity (NHR) which likely contributes to uncontrolled AR and breakthrough symptoms, and provides more effective AR symptom relief than INS monotherapy or INS + oral antihistamine. Finally, experts considered it likely that MP-AzeFlu should have a greater impact on asthma control than INS in co-morbid patients, but clinical data is required to back up existing pharmacoeconomic evidence. The next Rhinology Future Debate will be in held in Brussels in Dec 2019.",
keywords = "Journal Article, MP-AzeFlu, Nasal hyperresponsiveness, Allergic rhinitis, Patient preference, Asthma, Guidelines, LONG-TERM, INTRANASAL THERAPY, MOMETASONE FUROATE, NASAL HYPERREACTIVITY, asthma, ADVANCED DELIVERY-SYSTEM, patient preference, IMPACT, nasal hyperresponsiveness, FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE, ASTHMA, guidelines, QUALITY-OF-LIFE, allergic rhinitis",
author = "G Scadding and J Bousquet and C Bachert and Fokkens, {W J} and Hellings, {P W} and E Prokopakis and O Pfaar and D Price",
year = "2019",
doi = "10.4193/Rhin18.076",
language = "English",
volume = "57",
pages = "49--56",
journal = "American Journal of Rhinology",
issn = "1050-6586",
publisher = "OceanSide Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Rhinology future trends

T2 - 2017 EUFOREA debate on allergic rhinitis

AU - Scadding, G

AU - Bousquet, J

AU - Bachert, C

AU - Fokkens, W J

AU - Hellings, P W

AU - Prokopakis, E

AU - Pfaar, O

AU - Price, D

PY - 2019

Y1 - 2019

N2 - The 2nd Rhinology Future Debate, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases) was held in Brussels in December 2017. One of these debates addressed the position of MP-AzeFlu in allergic rhinitis (AR) treatment. The current article summarizes this debate; reviewing recent data, and exploring how this has been interpreted by experts and incorporated into AR management guidelines and a clinical decision support system (CDSS). The Allergic Rhinitis & its Impact on Asthma (ARIA) guideline position MP-AzeFlu firstline for the treatment of AR, and in preference to intranasal corticosteroids (INSs) during the first 2 weeks of treatment. The AR CDSS recommends MP-AzeFlu as one of the firstline treatments for patients with a visual analogue scale (VAS) score lower than 5/10 cm, and in preference (along with INS) for those with a VAS score equal or higher than5/10 cm. Panellists agreed that AR management should be kept as simple as possible, with some preferring a one treatment fits all approach, while others preferred a step-up approach. The need to change the AR management mentality was acknowledged, accepting that most patients use their medication as needed and use multiple treatments; AR medications are needed which have a very fast onset of action and which target breakthrough symptoms. Panellists agreed that MP-AzeFlu has a role to play here, since it has a 5 minute onset-of-action, provides clinically-relevant symptom relief in 15 mins and AR control in less than 3 days, targets nasal hyper-reactivity (NHR) which likely contributes to uncontrolled AR and breakthrough symptoms, and provides more effective AR symptom relief than INS monotherapy or INS + oral antihistamine. Finally, experts considered it likely that MP-AzeFlu should have a greater impact on asthma control than INS in co-morbid patients, but clinical data is required to back up existing pharmacoeconomic evidence. The next Rhinology Future Debate will be in held in Brussels in Dec 2019.

AB - The 2nd Rhinology Future Debate, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases) was held in Brussels in December 2017. One of these debates addressed the position of MP-AzeFlu in allergic rhinitis (AR) treatment. The current article summarizes this debate; reviewing recent data, and exploring how this has been interpreted by experts and incorporated into AR management guidelines and a clinical decision support system (CDSS). The Allergic Rhinitis & its Impact on Asthma (ARIA) guideline position MP-AzeFlu firstline for the treatment of AR, and in preference to intranasal corticosteroids (INSs) during the first 2 weeks of treatment. The AR CDSS recommends MP-AzeFlu as one of the firstline treatments for patients with a visual analogue scale (VAS) score lower than 5/10 cm, and in preference (along with INS) for those with a VAS score equal or higher than5/10 cm. Panellists agreed that AR management should be kept as simple as possible, with some preferring a one treatment fits all approach, while others preferred a step-up approach. The need to change the AR management mentality was acknowledged, accepting that most patients use their medication as needed and use multiple treatments; AR medications are needed which have a very fast onset of action and which target breakthrough symptoms. Panellists agreed that MP-AzeFlu has a role to play here, since it has a 5 minute onset-of-action, provides clinically-relevant symptom relief in 15 mins and AR control in less than 3 days, targets nasal hyper-reactivity (NHR) which likely contributes to uncontrolled AR and breakthrough symptoms, and provides more effective AR symptom relief than INS monotherapy or INS + oral antihistamine. Finally, experts considered it likely that MP-AzeFlu should have a greater impact on asthma control than INS in co-morbid patients, but clinical data is required to back up existing pharmacoeconomic evidence. The next Rhinology Future Debate will be in held in Brussels in Dec 2019.

KW - Journal Article

KW - MP-AzeFlu

KW - Nasal hyperresponsiveness

KW - Allergic rhinitis

KW - Patient preference

KW - Asthma

KW - Guidelines

KW - LONG-TERM

KW - INTRANASAL THERAPY

KW - MOMETASONE FUROATE

KW - NASAL HYPERREACTIVITY

KW - asthma

KW - ADVANCED DELIVERY-SYSTEM

KW - patient preference

KW - IMPACT

KW - nasal hyperresponsiveness

KW - FLUTICASONE PROPIONATE

KW - AZELASTINE HYDROCHLORIDE

KW - ASTHMA

KW - guidelines

KW - QUALITY-OF-LIFE

KW - allergic rhinitis

UR - http://www.scopus.com/inward/record.url?scp=85060648205&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/rhinology-future-trends-2017-euforea-debate-allergic-rhinitis

U2 - 10.4193/Rhin18.076

DO - 10.4193/Rhin18.076

M3 - Article

VL - 57

SP - 49

EP - 56

JO - American Journal of Rhinology

JF - American Journal of Rhinology

SN - 1050-6586

IS - 1

ER -